Items where authors include "Elhai, M."
Article
Yan, Q., Bruni, C., Garaiman, A. et al. (25 more authors) (2025) Post hoc comparison of the effectiveness of tocilizumab, rituximab, mycophenolate mofetil, and cyclophosphamide in patients with SSc-ILD from the EUSTAR database. Annals of the Rheumatic Diseases, 84 (4). pp. 620-631. ISSN 0003-4967
Roth, E., Bruni, C., Petelytska, L. et al. (244 more authors) (2025) Gastroesophageal reflux disease is associated with a more severe interstitial lung disease in systemic sclerosis in the EUSTAR cohort. Rheumatology. keaf016. ISSN 1462-0324
Kuster, S., Jordan, S., Elhai, M. et al. (104 more authors) (2022) Effectiveness and safety of tocilizumab in patients with systemic sclerosis: a propensity score matched controlled observational study of the EUSTAR cohort. RMD Open, 8 (2). e002477. ISSN 2056-5933
Elhai, M., Sritharan, N., Boubaya, M. et al. (167 more authors) (2022) Stratification in systemic sclerosis according to autoantibody status versus skin involvement: a study of the prospective EUSTAR cohort. The Lancet Rheumatology, 4 (11). e785-e794. ISSN 2665-9913
Conference or Workshop Item
Roth, E., Bruni, C., Petelytska, L. et al. (18 more authors) (2024) POS0230 Characteristics and disease course of SSc-ILD patients with gastroesophageal reflux – an analysis of the EUSTAR cohort. In: EULAR 2024 European Congress of Rheumatology, 12-15 Jun 2024, Vienna, Austria.
Proceedings Paper
Burja, B., Boubaya, M., Bruni, C. et al. (21 more authors) (2025) OP0081 Anti-Ro/SSA+/RF+ double seropositivity in systemic sclerosis is associated with more severe interstitial lung disease: A study from the EUSTAR database. In: Annals of the Rheumatic Diseases. EULAR 2025: European Congress of Rheumatology, 11-14 Jun 2025, Barcelona, Spain. Elsevier , pp. 71-72.
Burja, B., Boubaya, M., Bruni, C. et al. (21 more authors) (2025) OP0081 Anti-Ro/SSA+/RF+ double seropositivity in systemic sclerosis is associated with more severe interstitial lung disease: A study from the EUSTAR database. In: Annals of the Rheumatic Diseases. EULAR 2025: European Congress of Rheumatology, 11-14 Jun 2025, Barcelona, Spain. , pp. 71-72.
Burja, B., Welsing, P.M.J., Lescoat, A. et al. (16 more authors) (2025) POS0266 DEVELOPMENT OF AN ARTICULAR SCORE IN SYSTEMIC SCLEROSIS (ASSESS): IDENTIFICATION OF CORE INSTRUMENTS TO ASSESS DISEASE ACTIVITY. In: Annals of the Rheumatic Diseases. EULAR 2025: European Congress of Rheumatology, 11-14 Jun 2025, Barcelona, Spain. BMJ Publishing Group , pp. 532-533.
Burja, B., Boubaya, M., Bruni, C. et al. (16 more authors) (2024) OP0013 ANTI-Ro/SSA ANTIBODIES ARE PREDICTIVE OF A MORE SEVERE LUNG INVOLVEMENT IN PATIENTS WITH SYSTEMIC SCLEROSIS: A STUDY FROM THE EUSTAR HDATABASE. In: Annals of the Rheumatic Diseases. EULAR 2024 Congress, 12-15 Jun 2025, Vienna, Austria. Elsevier , pp. 1-2.